Olivier Ameisen
  • Olivier Ameisen

  • Date of birth: June 25, 1953
  • Born: in Paris, France.

  • Description: French-American cardiologist.

    Olivier Ameisen, MD, has proposed and tested an entirely new model for the treatment of addiction — not reduction of craving, but complete, rapid, effortless suppression of craving and other symptoms and consequences of addiction using high-dose baclofen therapy.

    Born and raised in Paris, in 1983 Olivier moved to New York to join the prestigious cardiology team at New York Hospital and Cornell University Medical College (now New York-Presbyterian Hospital and Weill Cornell Medical College), where he became respectively an associate attending physician and associate professor of clinical medicine (subsequently clinical associate professor of medicine), in addition to later establishing a busy private practice. As an active participant in cardiology research at New York Hospital/Cornell, he co-authored 16 papers in peer-reviewed medical journals on the evaluation of coronary artery disease and related topics.

    A lifelong sufferer from chronic anxiety and panic attacks, which medications and therapy failed to resolve, Olivier turned to alcohol as a form of self-medication. When he began to suffer from alcoholism in the late 1990s, he voluntarily closed his practice and devoted himself to recovering from the disease, trying singly and in combination all the established treatments as prescribed by his physicians. Nothing worked.

    Learning that in animal studies high-dose baclofen had suppressed addicted animals’ motivation to consume alcohol, amphetamine, cocaine, nicotine, and opiates, and postulating that these craving-suppressing effects could be transposed to humans, he experimented on himself and discovered that high-dose baclofen could completely free human patients from addiction.

    Subsequently he learned that high-dose baclofen has long been safely used without limiting side effects for comfort care in benign conditions in neurology. He then broke his anonymity to publish his discovery and offer a new model for the treatment of alcoholism and other addictions in a self-case report in the peer-reviewed medical journal Alcohol and Alcoholism. Since then, an increasing number of patients have obtained complete freedom from addiction by taking baclofen, as prescribed and supervised by their physicians, in accordance with his treatment protocol. To date, nearly one hundred such cases have been documented by clinical researchers.

    Olivier continues to devote his efforts to the treatment of addiction and to furthering research into baclofen and its mechanisms of action. He is the author of six peer-reviewed papers on addiction in specialist and general medical journals, including Alcohol and Alcoholism, The Journal of the American Medical Association, CNS Drugs, and The American Journal of Drug and Alcohol Abuse.